{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:11:48Z","timestamp":1778069508755,"version":"3.51.4"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the collective perception, uraemic patients are often identified as those undergoing dialysis. In reality, however, dialysis patients represent only a small fraction of the total uraemic population. Conservative estimates indicate that one in ten individuals in the industrialized world has some degree of renal dysfunction, meaning that approximately 700 million people are affected [GBD-Chronic Kidney Disease Collaboration. Global, regional, and national burden of Chronic Kidney Disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020;395:709\u201333]. These figures have rapidly made chronic kidney disease (CKD)\u2014the correct term for renal failure\u2014a global public health issue, owing both to its unsustainable economic burden for healthcare systems and its high mortality rate, estimated at 2.6 million deaths in 2017 [Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gipson D et al. US Renal Data System 2019 annual data report: epidemiology of kidney disease in the United States. Am J Kidney disease 2020;75:S1\u2013S64]. To mitigate the impact of this true epidemic, new strategies must prioritize early detection and prevention. The first step, however, is conceptual: CKD should no longer be regarded as an exclusively nephrological disorder but as a multisystem condition requiring the attention of internists, cardiologists, diabetologists, and general practitioners alike.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suag038","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:49:04Z","timestamp":1772628544000},"page":"v87-v90","source":"Crossref","is-referenced-by-count":0,"title":["Renal failure isn't just a nephrologist problem"],"prefix":"10.1093","volume":"28","author":[{"given":"Gennaro","family":"Cice","sequence":"first","affiliation":[{"name":"Department of Cardiology, Policlinico Casilino , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"2026050607120683900_suag038-B1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","journal-title":"Lancet"},{"key":"2026050607120683900_suag038-B2","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/s41591-019-0627-8","article-title":"Glomerular filtrationrate by differing measure, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease","volume":"25","author":"Lees","year":"2019","journal-title":"Nat Med"},{"key":"2026050607120683900_suag038-B3","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of Chronic Kidney Disease","volume":"3","author":"Kidney disease: Improving global outcomes (KDIGO) CKD work group","year":"2013","journal-title":"Kidney Int"},{"key":"2026050607120683900_suag038-B4","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results fromthe AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2026050607120683900_suag038-B5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in Chronic Kidney Disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2026050607120683900_suag038-B6","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2026050607120683900_suag038-B7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control in patients with type 2 diabetes: a meta-analysis of individual partecipant data from randomized controlled trials","volume":"5","author":"Zougas","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026050607120683900_suag038-B8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2i for prevention of kidney failure in patients with type 2 diabetes: a systematic rewiew and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026050607120683900_suag038-B9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026050607120683900_suag038-B10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with Chronic Kidney Disease","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050607120683900_suag038-B11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"REIN-2: multicenter, randomized, controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"2026050607120683900_suag038-B12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropaty","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026050607120683900_suag038-B13","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibitor for treatment of kidney diabetic nephropaty","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"2026050607120683900_suag038-B14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular mortality and kidney outcome with GLP1 receptor agonist in patients with type 2 diabetes: a systematic review and meta-analisys of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026050607120683900_suag038-B15","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralcorticoid receptor antagonist in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J Hypertens"},{"key":"2026050607120683900_suag038-B16","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on Chronic Kidney Disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/advance-article-pdf\/doi\/10.1093\/eurheartjsupp\/suag038\/67346605\/suag038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/28\/Supplement_5\/v87\/67346605\/suag038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/28\/Supplement_5\/v87\/67346605\/suag038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:12:17Z","timestamp":1778065937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/28\/Supplement_5\/v87\/8519648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":16,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2026,3,14]]},"published-print":{"date-parts":[[2026,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suag038","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,14]]}}}